Patents by Inventor Stephen Carl McKeown

Stephen Carl McKeown has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9604981
    Abstract: The present invention provides heterocyclic derivatives of formula (Ia) which activate the IP receptor. Activating the IP receptor signaling pathway is useful to treat many forms of PAH, pulmonary fibrosis and exert beneficial effects in fibrotic conditions of various organs in animal models and in patients. Pharmaceutical compositions comprising such derivatives are also encompassed.
    Type: Grant
    Filed: February 11, 2014
    Date of Patent: March 28, 2017
    Assignee: Novartis AG
    Inventors: Rebecca Butler, Catherine Leblanc, Stephen Carl McKeown, Steven John Charlton
  • Patent number: 9174985
    Abstract: The invention relates to salts of (7-(2,3-di-p-tolyl-7,8-dihydropyrido[2,3-b]pyrazin-5(6H)-yl)heptanoic acid which are useful for treating diseases affected by the activation of the IP receptor, pharmaceutical compositions that contain the salts and processes for preparing the salts are also described.
    Type: Grant
    Filed: January 11, 2013
    Date of Patent: November 3, 2015
    Assignee: Novartis AG
    Inventors: Catherine Leblanc, Stephen Carl McKeown, Anett Perlberg, Nicola Tufilli
  • Patent number: 9132127
    Abstract: The present invention provides heterocyclic derivatives which activate the IP receptor. Activating the IP receptor signaling pathway is useful to treat many forms of PAH, pulmonary fibrosis and exert beneficial effects in fibrotic conditions of various organs in animal models and in patients. Pharmaceutical compositions comprising such derivatives are also encompassed. Examples of compounds of the invention include the compounds according to Formula Ia, or a pharmaceutically acceptable salt thereof, and the compounds of the examples.
    Type: Grant
    Filed: April 30, 2014
    Date of Patent: September 15, 2015
    Assignee: Novartis AG
    Inventors: Steven John Charlton, Catherine LeBlanc, Stephen Carl McKeown
  • Patent number: 9115129
    Abstract: The present invention provides substituted pyrido[2,3-b]pyrazines which activate the IP receptor. Activating the IP receptor signaling pathway is useful to treat many forms of PAH, pulmonary fibrosis and exert beneficial effects in fibrotic conditions of various organs in animal models and in patients. Pharmaceutical compositions comprising such substituted pyride[2,3-b]pyrazines are also encompassed.
    Type: Grant
    Filed: January 11, 2013
    Date of Patent: August 25, 2015
    Assignee: Novartis AG
    Inventors: Steven John Charlton, Catherine Leblanc, Stephen Carl McKeown
  • Publication number: 20150011555
    Abstract: The invention relates to salts of (7-(2,3-di-p-tolyl-7,8-dihydropyrido[2,3-b]pyrazin-5(6H)-yl)heptanoic acid which are useful for treating diseases affected by the activation of the IP receptor, pharmaceutical compositions that contain the salts and processes for preparing the salts are also described.
    Type: Application
    Filed: January 11, 2013
    Publication date: January 8, 2015
    Applicant: NOVARTIS AG
    Inventors: Catherine Leblanc, Stephen Carl McKeown, Anett Perlberg, Nicola Tufilli
  • Publication number: 20150005311
    Abstract: The present invention provides heterocyclic derivatives which activate the IP receptor, processes for preparing them, pharmaceutical compositions comprising said derivatives and uses thereof. Activating the IP receptor signaling pathway is useful to treat many forms of PAH, pulmonary fibrosis and exert beneficial effects in fibrotic conditions of various organs in animal models and in patients.
    Type: Application
    Filed: January 11, 2013
    Publication date: January 1, 2015
    Applicant: NOVARTIS AG
    Inventors: Steven Carl Chatlton, Catherine Leblanc, Stephen Carl Mckeown
  • Publication number: 20140357642
    Abstract: The present invention provides heterocyclic derivatives which activate the IP receptor. Activating the IP receptor signaling pathway is useful to treat many forms of PAH, pulmonary fibrosis and exert beneficial effects in fibrotic conditions of various organs in animal models and in patients. Pharmaceutical compositions comprising such derivatives are also encompassed.
    Type: Application
    Filed: January 11, 2013
    Publication date: December 4, 2014
    Applicant: NOVARTIS AG
    Inventors: Steven Carl Chatlton, Catherine Leblanc, Stephen Carl McKeown
  • Publication number: 20140357641
    Abstract: The present invention provides heterocyclic derivatives which activate the IP receptor, processes for preparing them, pharmaceutical compositions comprising said derivatives and uses thereof. Activating the IP receptor signaling pathway is useful to treat many forms of PAH, pulmonary fibrosis and exert beneficial effects in fibrotic conditions of various organs in animal models and in patients.
    Type: Application
    Filed: January 11, 2013
    Publication date: December 4, 2014
    Applicant: NOVARTIS AG
    Inventors: Gurdip Bhalay, Steven Carl Chatlton, Mark Patrick Healy, Catherine Leblanc, Stephen Carl McKeown
  • Publication number: 20140243346
    Abstract: The present invention provides heterocyclic derivatives which activate the IP receptor. Activating the IP receptor signaling pathway is useful to treat many forms of PAH, pulmonary fibrosis and exert beneficial effects in fibrotic conditions of various organs in animal models and in patients. Pharmaceutical compositions comprising such derivatives are also encompassed. Examples of compounds of the invention include the compounds according to Formula Ia, or a pharmaceutically acceptable salt thereof, and the compounds of the examples.
    Type: Application
    Filed: April 30, 2014
    Publication date: August 28, 2014
    Applicant: NOVARTIS AG
    Inventors: Steven John CHARLTON, Catherine LEBLANC, Stephen Carl McKEOWN
  • Patent number: 8754085
    Abstract: The present invention provides heterocyclic derivatives which activate the IP receptor. Activating the IP receptor signaling pathway is useful to treat many forms of PAH, pulmonary fibrosis and exert beneficial effects in fibrotic conditions of various organs in animal models and in patients. Pharmaceutical compositions comprising such derivatives are also encompassed. Examples of compounds of the invention include the compounds according to Formula Ia, or a pharmaceutically acceptable salt thereof, and the compounds of the examples.
    Type: Grant
    Filed: July 14, 2011
    Date of Patent: June 17, 2014
    Assignee: Novartis AG
    Inventors: Steven John Charlton, Catherine Leblanc, Stephen Carl McKeown
  • Publication number: 20130102611
    Abstract: The present invention provides heterocyclic derivatives which activate the IP receptor. Activating the IP receptor signaling pathway is useful to treat many forms of PAH, pulmonary fibrosis and exert beneficial effects in fibrotic conditions of various organs in animal models and in patients. Pharmaceutical compositions comprising such derivatives are also encompassed. Examples of compounds of the invention include the compounds according to Formula Ia, or a pharmaceutically acceptable salt thereof, and the compounds of the examples.
    Type: Application
    Filed: July 14, 2011
    Publication date: April 25, 2013
    Applicant: Novartis AG
    Inventors: Steven John Charlton, Catherine Leblanc, Stephen Carl McKeown
  • Patent number: 7834013
    Abstract: The present invention relates generally to novel therapeutic compounds and more particularly to novel compounds, their use as GPR40 agonists, processes for their manufacture, and intermediates useful in their preparation.
    Type: Grant
    Filed: November 15, 2004
    Date of Patent: November 16, 2010
    Assignee: GlaxoSmithKline LLC
    Inventors: David Francis Corbett, Kate Anna Dwornik, Dulce Maria Garrido, Stephen Carl McKeown, Wendy Yoon Mills, Andrew James Peat, Terrence Lee Smalley, Jr.
  • Publication number: 20090239845
    Abstract: Compounds of formula (I) or a pharmaceutically acceptable derivative thereof: wherein Z, R1, R2a, R2b, R10, R11 and Rx are as defined in the specification, a process for the preparation of such compounds, pharmaceutical compositions comprising such compounds and the use of such compounds in medicine.
    Type: Application
    Filed: April 24, 2006
    Publication date: September 24, 2009
    Inventors: Elizabeth Ann Conway, Gerard Martin Paul Giblin, Mairi Gibson, Adrian Hall, Thomas George Christopher Hayhow, Mark Patrick Healy, David Nigel Hurst, Ian Reginald Kilford, Stephen Carl McKeown, Alan Naylor, Helen Susanne Price, Derek Anthony Rawlings
  • Publication number: 20090105257
    Abstract: The present invention relates generally to novel therapeutic compounds and more particularly to novel compounds, their use as GPR40 agonists, processes for their manufacture, and intermediates useful in their preparation.
    Type: Application
    Filed: November 15, 2004
    Publication date: April 23, 2009
    Inventors: David Francis Corbett, Kate Anna Dwornik, Dulce Maria Garrido, Stephen Carl McKeown, Wendy Yoon Mills, Andrew James Peat, Terrence Lee Smalley, JR.
  • Patent number: 6169091
    Abstract: Substituted heteroaromatic compounds of formula (A) wherein X is N or CH; in which (a) represents a fused 5, 6 or 7-membered heterocyclic ring and R3 is a group ZR4 wherein Z is joined to R4 through a (CH2)p group in which p is 0, 1, or 2 and Z represents a group V(CH2), V(CF2), (CH2)V, (CF2)V, V(CRR′), V(CHR) or V where R and R′ are each C1-4 alkyl and in which V is a hydrocarbyl group containing 0, 1 or 2 carbon atoms, carbonyl, dicarbonyl, CH(OH), CH(CN), sulphonamide, amide, O, S(O)m or NRb where Rb is hydrogen or Rb is C1-4 alkyl; and R4 is an optionally substituted C3-6 cycloalkyl or an optionally substituted 5, 6, 7, 8, 9 or 10-membered carbocyclic or heterocyclic moiety; or R3 is a group ZR4 in which Z is NRb, and NRb and R4 together form an optionally substituted 5, 6, 7, 8, 9 or 10-membered carbocyclic or heterocyclic moiety, are protein tyrosine kinase inhibitors.
    Type: Grant
    Filed: August 26, 1998
    Date of Patent: January 2, 2001
    Assignee: Glaxo Wellcome Inc.
    Inventors: George Stuart Cockerill, Stephen Barry Guntrip, Stephen Carl McKeown, Martin John Page, Kathryn Jane Smith, Sadie Vile, Alan Thomas Hudson, Paul Barraclough, Karl Witold Franzmann